Scientists mapped more than 1,800 protein-protein interactions tied to autism, and 87% of them had never been seen before, in a study published Thursday in the journal Science. The work used artificial intelligence and lab-grown brain organoids to trace how genetic mutations associated with autism may rewire the brain, while the federal machinery around autism research kept grinding toward another strategic plan vote and another round of spending decisions.
Who Gets Studied, Who Gets Decided For
The study’s most concrete fact is also its sharpest reminder of where power sits: researchers are trying to decode autism through a molecular map, while people with profound autism, who account for about 30% of people with autism spectrum disorder, are described as needing 24-hour care. That’s the human cost at the bottom of a system where research priorities, treatment paths, and funding streams are set far above the people most affected.
Study author Dr. Nevan Krogan, professor at the University of California, San Francisco and senior investigator at the nonprofit Gladstone Institutes, said, “You need this insight to ultimately develop drugs, and we’ve generated a map now that is providing essentially the molecular underpinnings of autism and pointing us in a multitude of different directions for ultimate drug discovery.” He added, “The hope would be at some point you’d be looking back and saying, ‘Ah, this map led to X, Y, and Z, and therefore we have now the first-ever treatment to autism.’ That’s the vision, and I believe that’s going to come to fruition at some point in the future.”
Krogan said he and his colleagues already have three programs underway to develop potential new therapies using insights from the study. The work from researchers at the University of California, San Francisco systematically mapped how genetic mutations tied to autism may influence interactions between proteins in the brain. They used an artificial intelligence system called AlphaFold to prioritize key mutations, then studied them in lab-grown brain organoids. The researchers said the proteins were “rewired” in the presence of the mutations.
The Map, the Money, the Gatekeepers
Krogan said, “AI is allowing us to study proteins that we could never have even dreamed of even a couple of years ago, and it’s providing an unprecedented light being shone on autism, the underlying biology behind autism.” He said the map is “the largest that has ever been done on autism.” He added, “It’s the largest map of its kind for any neuropsychiatric disorder, but it’s also the largest mutant map that’s ever been generated for any disease area.”
Fikri Birey, assistant professor in the Department of Human Genetics at Emory University School of Medicine, who was not involved in the study, wrote in an email, “The new study is really exciting in that it represents the most systematic protein-level view of autism risk we’ve had to date.” He added, “In the future, it may be possible to identify drugs that stabilize disrupted protein complexes or block pathological interactions, rather than trying to correct every individual autism-causing mutation,” and said the findings could help inform the disease-modeling research conducted in his own lab.
Autism experts and advocates praised the study, but the route from discovery to treatment still runs through institutions, funding decisions, and clinical gatekeeping. Alison Singer, president of the nonprofit Autism Science Foundation, wrote, “Today’s study shows where different autism genes converge on shared biological pathways, and those shared pathways could ultimately give us therapeutic targets relevant to much larger groups of autistic people, including people without an identified genetic cause. That is nothing short of a huge watershed moment for autism science.” She added, “For families of people with profound autism like mine, this is the kind of scientific advance we have been waiting for and praying for. Many people with profound autism have rare genetic variants and the promise of precision medicine has always been that understanding those variants would eventually allow us to move beyond treating symptoms and behaviors, and begin addressing the underlying biology.”
Singer also said, “There is still a lot of work ahead and these discoveries today need to be translated into drug candidates and then tested for safety and effectiveness, but the path from genetic discovery to treatment has just become much clearer.” Dr. Andy Shih, chief science officer at Autism Speaks, cautioned that translating the findings into therapies would take time. He wrote, “Translating these kinds of discoveries into therapies is a long process. This study provides valuable insights into potential targets, but much more research is needed before these findings can lead to clinical applications.”
What the Federal Apparatus Is Doing
Autism has become a major focus of the second Trump administration’s Department of Health and Human Services, under which the Interagency Autism Coordinating Committee helps develop and update the national strategic plan for autism research. A new draft plan is up for a committee vote on Thursday. Singer said she is not convinced the draft plan will push more research toward the biological targets highlighted in the new study. She said she worries the Trump administration may steer attention away from current science and toward an unproven link between vaccines and autism.
Singer wrote, “The federal plan for autism research deemphasizes genetics, neurodevelopment, and brain biology in favor of a broad injury model that is not consistent with the direction of contemporary autism science.” She added, “Redirecting limited federal research investments away from the strongest biological evidence will slow scientific progress precisely when these types of unprecedented opportunities for therapeutic development are emerging.”
Shih said he expects the new strategic plan will include more research into the genetic changes linked with autism. He wrote, “There is significant interest in understanding developmental trajectories in the new IACC strategic plan. And I would expect that continued investment in large-scale, data-driven approaches will lead to more studies examining how genetic factors contribute to autism and affect development.”
A separate New York Times report said studies of brain proteins may offer new targets for autism treatment. Reuters reported that U.S. advisory committee recommendations propose nearly doubling federal investment in autism-related research and related supports, including medical care, housing, aging and other priorities. The same state apparatus that sets the research agenda is also deciding how much money goes where, and who gets to wait for the next round of promises.